Evolution of HER2 expression after neoadjuvant therapy in locally advanced gastric cancer.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
398 patients with locally advanced gastric cancer who received neoadjuvant treatment (NAT) followed by gastrectomy between 2018 and 2023 at three medical centers in China.
I · Intervention 중재 / 시술
neoadjuvant treatment (NAT) followed by gastrectomy between 2018 and 2023 at three medical centers in China
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
PD-1/PD-L1 inhibitors and trastuzumab both increased pCR rates, but neither significantly impacted the rate of HER2 expression alterations among non-pCR patients. Reassessing HER2 status after NAT is essential for guiding HER2-targeted therapies.
HER2 is a crucial biomarker in gastric cancer, influencing both treatment strategies and patient prognosis.
APA
He J, Liu H, et al. (2025). Evolution of HER2 expression after neoadjuvant therapy in locally advanced gastric cancer.. iScience, 28(6), 112710. https://doi.org/10.1016/j.isci.2025.112710
MLA
He J, et al.. "Evolution of HER2 expression after neoadjuvant therapy in locally advanced gastric cancer.." iScience, vol. 28, no. 6, 2025, pp. 112710.
PMID
40520113 ↗
Abstract 한글 요약
HER2 is a crucial biomarker in gastric cancer, influencing both treatment strategies and patient prognosis. A multicenter retrospective study was conducted, including 398 patients with locally advanced gastric cancer who received neoadjuvant treatment (NAT) followed by gastrectomy between 2018 and 2023 at three medical centers in China. Alterations in HER2 expression after NAT were detected in more than 40% of patients, with a higher rate of decreased expression (26.0%) compared to increased expression (17.3%). Multivariate analysis indicated that HER2 status at diagnosis significantly influenced HER2 expression alteration. Patients with HER2 IHC 2+ tumors before NAT demonstrated an increased tendency for HER2 expression alterations after NAT. Decreased HER2 expression was associated with improved recurrence-free survival and overall survival. PD-1/PD-L1 inhibitors and trastuzumab both increased pCR rates, but neither significantly impacted the rate of HER2 expression alterations among non-pCR patients. Reassessing HER2 status after NAT is essential for guiding HER2-targeted therapies.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Zeaxanthin targets TOP2A to regulate autophagy and suppress lung cancer progression via the MAPK/ERK pathway.
- Harmine inhibits non-small cell lung cancer growth by targeting phosphodiesterase4D and inducing ferroptosis.
- A Comprehensive Assessment of the Causal Relationship Between Atopic Conditions and Pancreatic Cancer Risk: A Two-Sample Mendelian Randomization Study.
- Global research trends and focus on biomarkers in lung cancer immunotherapy: a comprehensive bibliometric insight and visualization analysis (2001-2025).
- Smart Magnetic Nanozyme for Multimodal Dynamic Regulation to Reverse Multidrug Resistance in Breast Cancer.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Creative Arts Therapy for Anxiety, Depression, and Quality of Life in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
- Building Hybrid Pharmacometric-Machine Learning Models in Oncology Drug Development: Current State and Recommendations.
- Integrative Computational Approaches to Prostate Cancer with Conditional Reprogramming and AI-Driven Precision Medicine.
- AllergoOncology in Review: Harnessing Allergy in the Field of Oncology to Improve Patient Outcomes.
- Three Strategic Pillars for Implementing Endoscopic Nipple-Sparing Mastectomy.
- Innovative Exercise in Routine Cancer Care: Insights from Eight Years of Integrated Oncological Exercise Therapy (OTT).